Cabio Biotech Wuhan Co Ltd
SSE:688089
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its 3-Year Average (2.5), the stock would be worth ¥23.6 (47% upside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1.7 | ¥16.03 |
0%
|
| 3-Year Average | 2.5 | ¥23.6 |
+47%
|
| 5-Year Average | 2.6 | ¥25.21 |
+57%
|
| Industry Average | 1.9 | ¥18.62 |
+16%
|
| Country Average | 1.9 | ¥18.48 |
+15%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
C
|
Cabio Biotech Wuhan Co Ltd
SSE:688089
|
2.7B CNY | 1.7 | 15.9 | |
| JP |
|
Shin-Etsu Chemical Co Ltd
TSE:4063
|
13.2T JPY | 3.1 | 27.8 | |
| US |
|
Sherwin-Williams Co
NYSE:SHW
|
78.8B USD | 3.8 | 30.7 | |
| US |
|
Ecolab Inc
NYSE:ECL
|
73.2B USD | 3.6 | 35.3 | |
| JP |
Y
|
Yasuhara Chemical Co Ltd
TSE:4957
|
10.8T JPY | 0.6 | 10.5 | |
| CN |
|
Wanhua Chemical Group Co Ltd
SSE:600309
|
280.3B CNY | 1.6 | 21.3 | |
| CH |
|
Givaudan SA
SIX:GIVN
|
25.7B CHF | 2.9 | 24 | |
| DK |
|
Novozymes A/S
CSE:NZYM B
|
165.6B DKK | 6.6 | 54.8 | |
| IN |
|
Asian Paints Ltd
NSE:ASIANPAINT
|
2.3T INR | 10.8 | 60.8 | |
| US |
|
PPG Industries Inc
NYSE:PPG
|
24B USD | 1.8 | 15.2 | |
| CH |
|
Sika AG
F:SIKA
|
19.9B EUR | 1.6 | 17.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.1 |
| Median | 1.9 |
| 70th Percentile | 3.4 |
| Max | 1 129 391.6 |
Other Multiples
Cabio Biotech Wuhan Co Ltd
Glance View
Cabio Biotech Wuhan Co Ltd is a China-based company principally engaged in biotechnology business. The Company is mainly engaged in the research and development, production and sales of polyunsaturated fatty acids arachidonic acid (ARA), algal oil docosahexaenoic acid (DHA) and sialic acid (SA), and natural beta-carotene products. Its products are mainly used in infant formula food, dietary supplements, nutritional health food and formula food for special medical purposes. The Company integrates industrial strain-oriented optimization technology, fermentation fine control technology, and efficient separation, purification and preparation technology, and provides nutrient products and innovative solutions for customers in the global nutrition and health field through sustainable microbial synthesis and manufacturing methods. The Company mainly conducts its business in domestic and overseas markets.
